Commentary on imaging in the REMODEL trial
Contributing authors: Iris Friedli (Consultant Senior Imaging Director), Paul Hockings (Senior Scientific Advisor) & Jonas Svensson (Imaging Director) @ Antaros Medical
Chronic kidney disease (CKD) remains a major global health challenge. While recent therapies such as SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists, have transformed outcomes, one critical question persists: in what way do these drugs protect the kidney? Understanding the mechanism of action (MoA) is more than academic curiosity; it is the foundation for precision medicine, smarter trial design, and better patient stratification.
Traditional efficacy trials tell us whether a drug works, but not how. This gap limits our ability to optimize treatment strategies and identify which patients will benefit most. Enter mechanistic kidney trials – designed to decode the biology behind clinical outcomes. And at the center of this evolution is magnetic resonance imaging (MRI).
Imaging as a game-changer in kidney trials
MRI has advanced to a point where kidney macro and microstructure, hemodynamics, perfusion, and adipose tissue compartments, can be assessed non-invasively, to provide insights into key pathways implicated in CKD progression.
The REMODEL trial, recently published in Kidney International and presented at ASN Kidney Week by Katherine Tuttle, exemplifies this approach. Designed to explore the mechanisms behind semaglutide’s beneficial effects on kidney disease outcomes, REMODEL combined advanced functional MRI with paired kidney biopsies, single-nucleus RNA sequencing (snRNAseq), spatial transcriptomics, and biomarker analysis. This multimodal design created a bridge between cellular-level insights and whole-organ physiology and linking mechanistic findings to clinical outcomes observed in the FLOW trial.
Feasibility and why imaging partnerships matter
Running a global mechanistic trial that includes advanced imaging brings unique challenges, but they can be overcome with the right approach. One of the biggest priorities in imaging-based trials is to make sure data collected across different sites is consistent and reliable. This means getting the most out of each scanner by setting up protocols according to gold-standard recommendations and ensuring that images are captured in the same way over time.
Once the images are collected, they need to be analyzed in a consistent and compliant way. Centralized analysis and quality checks are essential to keep data accurate and comparable across sites. Without this, data can become fragmented and insights less reliable.
Precise and accurate measurements ensure that observed differences reflect physiological changes rather than methodological variation, essential for interpreting treatment effects in clinical trials.
Equally important is the ability to interpret imaging results in relation to what they mean biologically and for drug development – to understand what the data truly means for drug development decisions.
This is where the choice of imaging partner becomes pivotal. A strong partner brings:
With the right support, imaging becomes a powerful tool rather than a barrier – helping turn complex data into clear insights.
Strategic implications for pharma
Why does this matter in drug development? Because imaging-driven mechanistic trials provide deeper insight into drug effects and can inform smarter go/no-go decisions earlier in development. Embedding these approaches in early phase trials could uncover critical biological pathways, optimize trial design, and reduce late-stage attrition.
Beyond the REMODEL trial, this methodology is shaping a framework for future kidney studies – one that integrates imaging biomarkers and other clinical endpoints to guide more informed development strategies.
Closing thought
REMODEL proves that complex, multimodal mechanistic trials are not only feasible when supported by the right expertise and infrastructure, but they can provide key insights into the pathophysiological interpretation of a drug’s mechanisms. At Antaros Medical, we’ve seen firsthand how advanced imaging, standardized protocols, and centralized analysis can turn complexity into clarity. Imaging is emerging as a strategic enabler for the next generation of kidney trials, where understanding how therapies work is key to unlocking their full potential.
Blog disclaimer
The views and opinions expressed in this article are solely those of the contributing author/s. These views and opinions do not necessarily represent those of Antaros Medical.
Contact details
If you have any questions regarding this article, please reach out to press@antarosmedical.com